Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07314164 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.
MinorTrial sites expanded: 38 → 41 locationsEligibility criteria expanded, about 7 words · Secondary endpoints: details revised at 3 of 13 entriesShow 2 more changesShow less
Eligibility criteria expanded, about 7 words
Secondary endpoints: details revised at 3 of 13 entries
MinorTrial sites expanded: 34 → 38 locationsv8
MinorSite details revised at 5 of 34 sitesv7
MinorTrial sites expanded: 28 → 34 locationsv6
MinorSite details revised at 7 of 28 sitesv5
MinorTrial sites expanded: 18 → 28 locationsv4
MinorStudy sites: 6 to 18v3
NotableTrial status: Not Yet Recruiting to RecruitingStudy sites: 0 to 6 · Start date changed from estimate of Dec 31, 2025 to Dec 17, 2025 · Secondary endpoints: details revised at 2 of 13 entriesv2Show 3 more changesShow less
Study sites: 0 to 6
Start date changed from estimate of Dec 31, 2025 to Dec 17, 2025
Secondary endpoints: details revised at 2 of 13 entries
MinorStudy First Submitted
Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study will assess how well cabozantinib works and how safe it is in adults with a type of cancer called neuroendocrine tumors (NETs).
These tumors can appear in all parts of the body. All participants in this study have already received at least one treatment that affects the whole body to help manage their cancer, but their disease has continued to grow.
The study will take place in regular hospitals and clinics in Germany and Austria.
It will follow about 150 participants who are taking cabozantinib as part of their usual care. Doctors will collect information from routine medical visits, tests, and scans to see how the cancer responds to treatment and how long participants stay on cabozantinib. They will also look at side effects and how the treatment affects participants' quality of life.
This is an observational study, which means that no extra tests or procedures will be done beyond what is normally used to care for participants with this condition.